



Integra LifeSciences Offers Surgeons More Foot Fixation Options With Next-Generation Total Foot System

July 18, 2013

PLAINSBORO, N.J., July 18, 2013 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the commercial launch of the Integra® Total Foot System 2, which addresses both reconstruction and acute fractures of the forefoot, midfoot and hindfoot. The Total Foot System 2 enhances the current system by offering a wider variety of plates to better meet surgeons' needs. The plates are available in multiple sizes to accommodate varying patient anatomy, and can be further contoured to fit individual patient needs.

"The Total Foot System 2 exhibits our ability to adapt to the evolving market, by taking an existing system and making it better," said Robert Paltridge, Integra's President, Extremity Reconstruction. "Our next-generation system gives surgeons more options and greater flexibility, so they can choose the best treatment for their patients."

Integra's Total Foot System 2 will be available at Integra's booth 511 at the 2013 AOFAS Annual Meeting in Hollywood, Florida, July 17-20, 2013. Integra will also offer live demonstrations and opportunities for hands-on experience of its products.

Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. For more information, please visit www.integralife.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2012 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: United States:

Integra LifeSciences Holdings Corporation

Gianna Sabella

Director, Corporate Communications

(609) 936-2389

gianna.sabella@integralife.com